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Medulloblastoma (MB) is one of the most common pediatric cancers, likely originating
from abnormal development of cerebellar progenitor neurons. MicroRNA (miRNA) has
been shown to play an important role in the development of the central nervous system.
Microarray analysis was used to investigate miRNA expression in desmoplastic MB from
patients diagnosed at a young age (1 or 2 years old). Normal fetal or newborn cerebellum
was used as control. A total of 84 differentially expressed miRNAs (64 downregulated and
20 upregulated) were found. Most downregulated miRNAs (32/64) were found to belong
to the cluster of miRNAs at the 14q32 locus, suggesting that this miRNA locus is regulated
as a module in MB. Possible mechanisms of 14q32 miRNAs downregulation were investi-
gated by the analysis of publicly available gene expression data sets. First, expression of
estrogen-related receptor-γ (ESRRG), a reported positive transcriptional regulator of some
14q32 miRNAs, was found downregulated in desmoplastic MB. Second, expression of the
parentally imprinted gene MEG3 was lower in MB in comparison to normal cerebellum,
suggesting a possible epigenetic silencing of the 14q32 locus.miR-129-5p (11p11.2/7q32.1),
miR-206 (6p12.2), and miR-323-3p (14q32.2), were chosen for functional studies in DAOY
cells. Overexpression of miR-129-5p using mimics decreased DAOY proliferation. No effect
was found with miR-206 or miR-323 mimics.
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INTRODUCTION
Medulloblastoma (MB) is an embryonic tumor of the cerebellum
and the most common malignant brain tumor in childhood, likely
originating from abnormal development of cerebellar progenitor
neurons (1, 2). Transcriptional profiling of large number of MB
samples unraveled the existence of at least four distinct molec-
ular subgroups: (i) Wingless (Wnt) group, (ii) Sonic Hedgehog
(SHH) group, (iii) Group 3 and (iv) Group 4 (3, 4). These various
subtypes of MB are suggested to arise from different populations
of precursor or stem cells which form the cerebellum (5–8). This
transcriptome-based classification has opened new avenues for the
understanding of the molecular mechanism contributing to MB.
MicroRNAs (miRNAs) are suggested to play an important role
in controlling the development of the central nervous system
(CNS) by regulating cell proliferation and differentiation, as well
as apoptosis (9). miRNAs are small non-coding RNA molecules
of ∼22–25 nucleotides that post-transcriptionally downregulate
gene expression by binding the 3′-untranslated region (UTR) of
protein coding transcripts, resulting in either mRNA cleavage or
translational repression (10, 11). miRNA expression profiling of
both mouse and human MB has led to the identification of sig-
natures associated with the molecular subgroups of MB, tumor
diagnosis, and response to treatment, as well as novel targets of
potential clinical relevance (12–15). Previous studies, however,
interrogated limited number of miRNAs and included adult cere-
bellum in the normal control group. We investigated the expres-
sion profile of 847 miRNA in primary human desmoplastic MB of
younger children in comparison to normal fetuses or newborn
cerebellum. Eighty-four miRNAs were found to be differential
expressed in MB, most of them belonging to the cluster 14q32.
Possible mechanisms of 14q32 locus downregulation were inves-
tigated by the analysis of publicly available gene expression data
set. Functional studies using mimic miR-129-5p (11p11.2/7q32.1),
miR-206 (6p12.2), and miR-323-3p (14q32.2) and the DAOY
cell line, suggested a suppressive role for miR-129-5p in MB
proliferation.
MATERIALS AND METHODS
PRIMARY MEDULLOBLASTOMA TISSUE SAMPLES
Surgical specimens were obtained from 1 to 5 years old children
(n= 10), with desmoplastic MB (Table 1). Of note, microarray
analyses were performed with MB samples from children with
1–2 years old. Desmoplastic MBs belong, with rare exceptions, to
the SHH molecular subgroup (13–16). All MB samples used in
the present study had high mRNA levels of PTCH1 and low lev-
els of OTX2 (Figure A1 in Appendix), in comparison to normal
cerebellum, which is in keeping with the differential transcrip-
tional profile of SHH tumors (3). Normal cerebellum tissues were
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Table 1 | Summary of the medulloblastoma samples included in the
study.
Medulloblastoma Age at diagnosis Gender Histology
MB 1a 1 M N/D
MB 2a 1 F N/D
MB 3a 2 M D
MB 4a 2 M N/D
MB 5a 1 M N/D
MB 6a 2 M N/D
MB 7 5 M N/D
MB 8 5 M D
MB 9 4 M D
MB 10 5 M N/D
aSamples used in Affymetrix miRNA microarray analysis; F= female; M=male;
D=desmoplastic; N/D=nodular/desmoplastic.
obtained from 22 to 39 weeks old fetal and newborn (NW) autopsy
(n= 8) (Table 2). Ethical approvals were obtained from the Eth-
ical Research Committee of the Faculdade de Ciências Médicas
(n°656/2009), CAISM (n°064/2010), the Ethical Research Com-
mittee of Centro Infantil Boldrini (n°1.90-030710), and National
Committee of Ethics in Research (CONEP) n°0005.0.144.146-09.
Subtyping of MB was obtained by histological analysis.
TOTAL RNA ISOLATION AND ANALYSIS OF GLOBAL miRNA
EXPRESSION
Total RNA was extracted by Trizol™ (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions, with an addi-
tional overnight precipitation step at −20°C with isopropanol
(Merck). RNA quantification was carried out in a Qubit Quanti-
tation Platform (Invitrogen) and RNA quality was analyzed via gel
electrophoresis. Five hundred nanograms of RNA from 12 samples
(6 MB and 6 fetal cerebellum) were labeled with the 3′-DNA Flash-
Tag Biotin HSR kit (Genisphere, Hatfield, PA, USA) and hybridized
to GeneChip miRNA Array 1.0 (Affymetrix Inc., Santa Clara, CA,
USA), which comprises 847 human miRNAs. Data was acquired
using a GeneChip Scanner 3000 7G (Affymetrix).
VALIDATION OF miRNA DEREGULATION BY QUANTITATIVE REAL-TIME
PCR
Reverse transcription (RT) and quantitative real-time RT-PCR
(RT-qPCR) analysis were carried out using commercially avail-
able TaqMan microRNA assays (Applied Biosystems, Foster City,
CA, USA) and a 7500 Real-time PCR System (Applied Biosys-
tems). RT reactions (50 ng of total RNA) were performed in a
15µl final volume containing specific stem-loop primers for each
miRNA (129-5p, 206, 323-3p, 495, and internal control small RNA,
RNU6B), 10× RT Buffer, dNTPs, reverse transcriptase, RNase
inhibitor, and water in 96-well plates. Thermal cycling included
30 min at 16°C, 30 min at 42°C, and a final step of RT inactiva-
tion for 5 min at 85°C. PCR reactions were performed in a 10µl
final volume containing 5µl TaqMan Universal Master Mix II,
without UNG (Applied Biosystems), 3.5µl water, 0.5µl TaqMan
microRNA assay, and 1µl cDNA. Thermal cycling included an ini-
tial step of 10 min at 95°C for Taq activation followed by 40 cycles
Table 2 | Summary of the normal cerebellum tissues.
Normal cerebellum Gestational age Gender Diagnosis
C1 37 M Bilateral renal agenesis
C2a 39 M Hydropsy
C3a 22 – NM
C4a 31 M NM
C5a 36 – NM
C6a 24 M NM
C7 30 – Cardiopathy
C8a 26 M NM
aSamples used in Affymetrix miRNA microarray analysis; F= female; M=male;
NM=no malformation and no aneuploidy.
of 15 s denaturation at 95°C and 1 min of annealing/extension at
60°C. Each reaction was performed in triplicate and the miRNAs
expression levels were normalized against RNU6B. The threshold
cycle numbers (Ct) were calculated by relative quantification using
the 2−∆∆Ct method, as described by Livak and Schmittgen (17).
One of the control samples was chosen as calibrator.
CELL LINES
Four human MB cell lines were utilized: DAOY (HTB 186),
D283 Med (HTB185), and D431 Med (HTB-187) were obtained
from American Type Culture Collection (ATCC). The MB cell
line, MEB-Med-8A, was kindly provided by Prof. T. Pietsch
(18). The MB cell lines DAOY, D283 Med, and MEB-Med-8A
were maintained in High Glucose Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 1 mM sodium pyruvate
(PAA),l-glutamine, 1% penicillin/streptomycin (Invitrogen, Karl-
sruhe, Germany), and 10% fetal bovine serum (FBS, Invitro-
gen). The MB cell line D341 Med was maintained in DMEM
with l-glutamine supplemented with 1 mM sodium pyruvate, 1%
penicillin/streptomycin, and 10% Human Serum (HS, PAA, UK).
TRANSIENT TRANSFECTION OF miRNAs
DAOY cells (1.5× 105) were seeded in six-well plates in 2 ml of
RPMI-1640 medium (Cultilab, Campinas, Brazil) supplemented
with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA) and peni-
cillin/streptavidin (Cultilab). Transfection of miRVana miRNA
mimics (Invitrogen Ambion, Austin, TX, USA) of miR-206, miR-
129-5p, miR-323-3p, or miRVana miRNA mimic negative con-
trol #1 (referred to as scrambled) was carried out 24 h after
seeding, in a final concentration of 3 nM, using Lipofectamine
RNAiMAX reagent (Invitrogen) according to the manufacturer’s
recommendation. Efficiency of transfection was evaluated 24
post-transfection by RT-qPCR using total RNA.
CELL VIABILITY: MTS ASSAY
Cell survival/proliferation after the transfection with mimic-
miRNAs was evaluated by using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Wallisellen,
Switzerland), a colorimetric [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)]-2H-tetrazolium
inner salt (MTS) assay. Briefly,mimic-miR-206,mimic-miR-129-5p,
and mimic-miR-323-3p or mimic-negative control #1 transfected
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Table 3 | Deregulated miRNA in desmoplastic medulloblastoma
compared to normal cerebellum.
Our miRNA profile
(84)
Chromosomal
localization
Fold
change
Reference
DOWNREGULATED
hsa-miR-206 6p12.2 −7.53 (29)
hsa-miR-219-2-3p 9q33.3 −6.64 (52)
hsa-miR-383 8p22 −6.56 (12, 55, 56)
hsa-miR-138 16q13.3/3p21.32 −5.16 (12, 14)
hsa-miR-323-3p 14q32.2 −4.96 (12, 52)
hsa-miR-122 18q21.31 −4.82
hsa-miR-105 Xq28 −4.66
hsa-miR-129-5p 11p11.2/7q32.1 −4.56 (23)
hsa-miR-935 19q13.43 −4.53 (52)
hsa-miR-329 14q32.2 −4.48
hsa-miR-129-3p 11p11.2/7q32.1 −4.43
hsa-miR-650 22q11.21 −4.19
hsa-miR-184 15q24.3 −4.14
hsa-miR-370 14q32.2 −3.99 (12)
hsa-miR-433 14q32.2 −3.96 (29)
hsa-miR-138-2* 16q13.3/3p21.32 −3.91
hsa-miR-487b 14q32.2 −3.82 (29)
hsa-miR-487a 14q32.2 −3.78
hsa-miR-758 14q32.2 −3.65
hsa-miR-485-5p 14q32.2 −3.60
hsa-miR-138-1* 16q13.3/3p21.32 −3.55
hsa-miR-382 14q32.2 −3.53 (12, 29)
hsa-miR-504 Xq26.3 −3.45 (52)
hsa-miR-128 2q21.3/3p22.3 −3.43 (12, 14, 51, 59)
hsa-miR-490-5p 7q33 −3.42
hsa-miR-770-5p 14q32.2 −3.35
hsa-miR-410 14q32.2 −3.30 (29)
hsa-miR-432 14q32.2 −3.29
hsa-miR-485-3p 14q32.2 −3.02
hsa-miR-490-3p 7q33 −2.88
hsa-miR-381 14q32.2 −2.73 (12)
hsa-miR-377* 14q32.2 −2.72
hsa-miR-7 15q25.3/19p13.3/9q21.32 −2.72 (12, 14)
hsa-miR-124 20p23.1/8q12.3/8p23.1 −2.71 (12, 14, 29, 48,
49)
hsa-miR-323-5p 14q32.31 −2.69 (12)
hsa-miR-873 9p21.1 −2.65
hsa-miR-129* 11p11.2/7q32.1 −2.63
hsa-miR-338-5p 17q25.3 −2.61 (14)
hsa-miR-409-5p 14q32.2 −2.61
hsa-miR-874 5q31.2 −2.46
hsa-miR-495 14q32.2 −2.46 (52)
hsa-miR-885-5p 3p25.3 −2.45
hsa-miR-376c 14q32.2 −2.43 (52)
hsa-miR-299-5p 14q32.2 −2.41
hsa-miR-539 14q32.2 −2.40 (52)
hsa-miR-127-5p 14q32.2 −2.35 (12, 29)
hsa-miR-127-3p 14q32.2 −2.35 (52, 59)
hsa-miR-411* 14q32.2 −2.30
(Continued)
Our miRNA profile
(84)
Chromosomal
localization
Fold
change
Reference
hsa-miR-125b-1* 11q24.1/21q21.1 −2.27
hsa-miR-411 14q32.2 −2.23 (29)
hsa-miR-379 14q32.2 −2.22 (29, 52)
hsa-miR-431* 14q32.2 −2.22
hsa-miR-767-5p Xq28 −2.20
hsa-miR-139-3p 11q13.4 −2.17
hsa-miR-154 14q32.2 −2.16 (12)
hsa-miR-1224-5p 3q27.2 −2.15
hsa-miR-187 18q12.1 −2.14 (12)
hsa-miR-95 4p16.1 −2.10 (14)
hsa-miR-369-5p 14q32.2 −2.05
hsa-miR-665 14q32.2 −2.05
hsa-miR-494 14q32.2 −2.03 (52)
hsa-miR-134 14q32.2 −2.03 (12, 29)
hsa-miR-346 10q23.2 −2.01 (12, 13)
hsa-miR-324-5p 17p13.1 −2.00 (12, 50)
UPREGULATED
hsa-miR-199b-3p 9q33.3 4.56 (12)
hsa-miR-199a-3p 19p13.2/1q24.1 4.49
hsa-miR-199a-5p 19p13.2/1q24.1 4.14 (28)
hsa-miR-21 17q22 3.70 (12–14, 29, 31)
hsa-miR-214 1q24.2 3.59
hsa-miR-19a 13q31.3 3.11 (12–14)
hsa-miR-92a-1* 13q31.3/Xq26.2 3.06
hsa-miR-214* 1q24.2 2.93
hsa-miR-34a 1p36.23 2.78 (13, 30, 53)
hsa-miR-18b Xq26.2 2.74
hsa-miR-422a 15q22.2 2.72 (14)
hsa-miR-34a* 1p36.23 2.58 (14)
hsa-miR-574-3p 4p14 2.49 (14)
hsa-miR-378 5q32 2.39 (14)
hsa-miR-1244 12p13.2/12p13.31/
2q37.1/5q23.1
2.39
hsa-miR-18a 13q31.3 2.39 (12–14)
hsa-miR-93* 7q22.1 2.26
hsa-miR-497 17p13.1 2.17 (13)
hsa-miR-195* 17p13.1 2.14
hsa-miR-216a 2p16.1 2.07 (14)
Deregulated miRNAs previously described in human primary medulloblastoma
compared with normal cerebellum or cell lines: (i) miRNAs found downregulated
in Ref. (12–14, 23, 26, 29, 48–52, 55, 56, 59); (ii) miRNAs found upregulated in
Ref. (12–14, 28–31, 53).
cells were harvested 20 h after transfection and seeded in triplicate
in 96-well plate (1,500 cells/well) in serum-free RPMI-1640 (Cul-
tilab). At 24, 48, or 72 h post-transfection (i.e., 4, 28, or 52 h after
passage to the 96-well plate) cells were incubated for 1 h with
MTS reagent and absorbance read at 492 nm (reference wave-
length 620 nm) using an ASYS Expert Plus Microplate Reader
(Biochrom, Holliston, MA, USA). Three independent experiments
were performed.
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APOPTOSIS ASSAY
DAOY cells transfected with miR-206, 129-5p, 323-3p, or scramble
mimics were cultured for 24 h in serum-free RPMI-1640 (Culti-
lab), harvested and part of it was resuspended in the appropriate
binding buffer, stained with FITC-conjugated Annexin V (BD Bio-
sciences, San Jose, CA, USA) and propidium iodide at room tem-
perature for 15 min, and subsequently analyzed by flow cytometry
in a FACS Canto II (Becton Dickinson). The remaining cells were
replated in six-well plates for another 24 h culture period in serum-
free RPMI-1640 (Cultilab) and harvested 48 h post-transfection
for Annexin V labeling.
STATISTICAL ANALYSIS AND BIOINFORMATICS METHODS TO
SIGNALING PATHWAY PREDICTION
MicroRNA expression was analyzed in R environment1 using
the packages Affy and RankProd from Bioconductor (19–21).
The MB miRNA profile was compared to the cerebellum pro-
file. Differentially expressed miRNAs were selected according to
the fold change ≥2.00 and p-value ≤0.05. Heat maps were cre-
ated using tools of the MetaboAnalyst 2.02. Signaling pathways
were prospected by DIANA-miRPath (microT-v4.0, beta ver-
sion)3. The input dataset enrichment analysis was performed
by Pearson’s chi-squared test and each pathway was represented
by the negative natural logarithm of the P-value (−ln P).
The Ingenuity Pathway Analysis (IPA) software4 was used to
identify possible pathways associated to differentially expressed
miRNAs.
Comparisons of RT-qPCR values from MB versus normal
cerebellum were performed by the Mann–Whitney test. Cell pro-
liferation results, at each time point, from mimic miRNA trans-
fections versus mimic-negative control #1 were analyzed by the
two-tailed unpaired t -test. Alpha error of P = 0.05 was tolerated.
The GraphPad Prism 5 software was used throughout.
RESULTS
IDENTIFICATION OF DIFFERENTIALLY EXPRESSED miRNAs IN
DESMOPLASTIC MBs OF 1–2 YEARS OLD CHILDREN
Global miRNA profiles were generated for primary MB of the
desmoplastic subtype and most likely SHH molecular subgroup
(n= 6), and normal fetal/NW cerebellum (n= 6). Eighty-four
miRNAs (64 miRNAs downregulated and 20 miRNAs upregu-
lated) were considered to be differentially expressed (fold change
≥2.0, p≤ 0.05) in MB in comparison to normal fetal/NW cere-
bellum (Table 3; Figure 1). Among these 84 miRNAs, 46 had
been previously described as deregulated in human primary MB
(Table 3), and only 8 were previously validated by functional assays
(Table 4). Upregulation of miRNAs from the miR-17∼ 92 cluster
(in this work miR-18a, 19a, and 92a-1) and downregulation of
miR-324-5p were previously described in human MB of the SHH
subgroup (12, 13). Of especial note, 32 of the 64 downregulated
miRNAs belong to a large cluster on human chromosome 14q32
(Figure 1; Table 3).
1www.r-project.org
2www.metaboanalyst.ca
3http://diana.cslab.ece.ntua.gr/pathways/index_multiple.php
4http://www.ingenuity.com/
SIGNALING PATHWAYS ANALYSIS BY DIANA
Signaling pathways putatively altered by MB deregulated miRNA
were depicted by DIANA-miRPath. The list of the top 20 pathways
is shown in Table 5. The Ribosome pathway was only pointed by
the list of downregulated miRNAs. Adherens junction, oxidative
phosphorylation, and TGF-beta signaling pathways showed higher
enrichment when the list of downregulated miRNAs was used in
the analysis. On the other hand, the MAPK pathway and genes
associated to cancer showed higher enrichment when upregulated
miRNAs were used in the analysis.
Interestingly, oxidative phosphorylation, TGF-beta signaling
pathway, and ubiquitin mediated proteolysis were enriched in the
list of 14q32 miRNAs.
INGENUITY PATHWAY ANALYSIS
Network analysis by IPA identified two networks as putative
targets for 73 out of the 84 MB miRNAs. Networks were
prospected considering only relationships that were experimen-
tally observed. Interestingly, both networks were enriched with
miRNAs belonging to the 14q32 cluster.
Network 1 (Figure 2A) included 13 miRNAs of the 14q32 clus-
ter (also known as miR-154 cluster), which were all downregulated
in MB samples (miR-154, 323-3p, 323-5p, 369-5p, 377*, 381, 382,
409-5p, 410, 485-3p, 487a, 487b, 539) and were depicted by IPA as
having direct interactions with BCL2L11, JUN, BIRC5, MAP2K4,
and NR0B2. BIRC5 and BCL-2 have anti-apoptotic roles, and are
expected to be at increasing levels in MB as all miRNAs connecting
to these genes were found downregulated (Figure 2A).NR0B2 and
JUN were suggested in this network as candidate genes controlling
the expression of the 14q32 miRNA cluster.
Again, most miRNAs shown in Network 2 (Figure 2B) belong
to the 14q32 cluster (miR-127-3p, 127-5p, 134, 379, 411, 432, 433,
495, and 758). In this case,NR0B2 and estrogen-related receptor-γ
(ESRRG) were suggested as candidate genes controlling the expres-
sion of the 14q32 miRNA cluster. Insulin appeared in Network 2
as indirectly controlling the expression of miR-206, 324-5p, 432,
and 95.
RT-qPCR VALIDATION OF SOME DEREGULATED miRNAs
miR-323-3p and 495, both belonging to cluster 14q32, were chosen
for validation by RT-qPCR. In addition, miR-206 and miR-129-
5p were chosen for analysis because of their high fold change
(see Table 3), lack of previous functional studies and possible
oncogenic role. miR-206 expression was reported to inhibit cell
proliferation in breast cancer cells (22). miR-129 is reported to be
significantly downregulated in pediatric brain tumors compared
to normal tissues (23). Most importantly, miR-129 downregu-
lation is associated to SOX4 overexpression in endometrial and
gastric cancers (24, 25). SOX4 is upregulated and has prognostic
impact in MB (26, 27).
Real-time RT-qPCR analysis were performed with all samples
used in the microarray analysis (n= 6 MB and n= 6 cerebel-
lum) plus four other samples of MB (Table 1) and two new
fetal/NW cerebellum controls (Table 2). As expected, miR-206
(p= 0.0001; Mann–Whitney test), miR-129-5p (p= 0.002), miR-
323-3p (p= 0.014), and miR-495 (p= 0,054), had lower expres-
sion in MB in comparison to normal cerebellum (Figure 3),
thus confirming our microarray findings. Expression of miR-206,
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FIGURE 1 | Hierarchical clustering analysis of medulloblastoma and normal cerebellum. Unsupervised hierarchical cluster analysis representing the 84
miRNAs expressed in medulloblastoma samples versus normal cerebellum. 14q32 miRNAs are depicted by a left vertical line. -st, star.
129-5p, 323-3p, and 495 were also investigated in a representative
panel of MB cell lines. Compared with normal human cerebel-
lum, miR-206, 129-5p, and 323-3p expression were found to be
downregulated in all MB cell line tested (Figure 3).
UPREGULATION OF miR-206, 129-5p, AND 323-3p IN DAOY CELLS
As a first approach to investigate the functional significance of
miRNAs downregulation in MB, DAOY cells were transiently
transfected with mimics of miR-206, 129-5p, 323-3p, or negative
control #1. Transfection efficiency was confirmed by RT-qPCR
(Figure A2 in Appendix). Twenty hours post-transfection, cells
were collected and seeded in 96-well plates in serum-free medium.
DAOY cells survive and even proliferate in serum-free medium for
a short period of time. As shown in Figure 4, no consistent differ-
ences in proliferation were found in transfections with miR-206
and miR-323-3p. On the contrary, transfections with miR-129-5p
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Table 4 | miRNAs validated by functional assay in human and mouse medulloblastoma.
miRNA Deregulation Cells Functional assaya Target genes Reference
124 Down Primary human MB, cell lines ↑ Cell cycle progression at G1 CDK6 (48, 49)
↓ Cell proliferation SLC16A1
324-5p Down Primary human and mouse MB, cell lines ↓ Cell proliferation SMO (50)
326 GLI1
125p
9 Down Primary human MB, cell lines ↑ Apoptosis Trkc (12)
125a ↓ Cell proliferation
199b-5p Up Primary human and mouse MB, cell lines ↑ Cell cycle progression at G1 HES1 (28)
↓ Cell proliferation
128 Down Primary human and mouse MB ↓ Cell proliferation BMI-1 (51)
↑ Cell senescence
21 Up Primary human MB, cell lines ↓ Cell migration PDCD4 (31)
935 Down Primary human MB, cell lines – KIAA0232 (52)
SLC5A3
TBC1D9
ZFAND6
34a Down MB cell lines ↑ Apoptosis MAGE-A (30, 53)
↑ Cell cycle progression at S/phase and G2/M Dll1
↓ Cell proliferation Notch1
↑ Cell senescence Notch2
512-5p Down Primary human MB, cell lines – MYCC (54)
383 Down Primary human MB, cell lines ↑ Apoptosis PRDX3 (55, 56)
↑ Cell cycle progression at G1
↓ Cell proliferation
183∼96∼ Down MB cell lines ↑ Cell cycle progression at AKT (57)
182 G0/G1 and G2
↓ Cell migration
↓ Cell proliferation
218 Down MB cell lines ↓ Cell migration CDK6 (58)
↓ Cell proliferation REST
Underlined miRNAs are miRNAs also found deregulated in the present study;
aresults of ectopic expression or knockdown assays; MB=medulloblastoma.
resulted in a significant decrease in DAOY cell proliferation, as
evaluated by the MTS assay (Figure 4). Similar experiments were
conducted to evaluate cell survival and apoptosis by the Annexin
V and propidium iodide staining methodology. No significant
differences were found on cell viability or apoptosis after miR-
206, miR-129-5p, and miR-323-3p transfections in comparison to
control (Figure 4; Figure A3 in Appendix, respectively).
DISCUSSION
We investigated the expression profile of miRNAs in pri-
mary human MB of desmoplastic histology and SHH mole-
cular subgroup, in comparison to normal fetal/newborn cere-
bellum. Eighty-four miRNAs were found to be differentially
expressed in MB. The majority of these differentially expressed
miRNAs were downregulated in comparison to normal cere-
bellum, corroborating previous studies. Most upregulated miR-
NAs identified in our study (12 out of 20) had been previ-
ously described in MB (12–14, 23, 28–32). On the contrary,
31 out of the 64 downregulated miRNAs are here described
for the first time in association to MB (Table 3). Differences
may be explained by the fact that a more comprehensive ver-
sion of Affymetrix miRNA microarray was used in the present
study. Moreover, previous studies included different subtypes of
MB and a mix of children and adults cerebellum samples in
their analysis (12, 13, 29). We believe that analysis on more
uniform groups of both cancer and control samples may have
helped us in detecting some smaller but consistent differences
between groups.
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Table 5 |Top 20 pathways predicted by DIANA-miRPath analysis.
Pathway signaling All deregulated miRNAs Downregulated miRNAs Upregulated miRNAs 14q32 miRNAs
P -valuea
Ribosome 30.03 25.34 – 17.78
Axon guidance 24.96 19.98 17.95 17.7
Wnt signaling pathway 18.6 19.34 17.71 16.99
Focal adhesion 16.65 17.02 15.13 14.73
Adherens junction 16.23 20.37 12.18 16.6
Oxidative phosphorylation 14.95 14.76 7.34 14.45
ErbB signaling pathway 14.8 11.03 9.14 9.02
Metabolism of xenobiotics by cytochrome P450 14.06 15.33 3.15 10.01
Renal cell carcinoma 13.48 13.21 9.35 11.64
TGF-beta signaling pathway 12.4 14.11 5.64 17.56
Regulation of actin cytoskeleton 12.25 11.52 7.86 10.63
Chronic myeloid leukemia 12.06 11.02 8.14 10.54
MAPK signaling pathway 11.86 9.81 17.06 12.4
Colorectal cancer 11.72 13.24 9.79 16.92
Glioma 10 8.47 16.21 7.23
Pancreatic cancer 9.69 9.61 13.18 5.83
Melanogenesis 9.4 9.32 9.07 10.59
Ubiquitin mediated proteolysis 9.28 10.09 6.63 11.11
Prostate cancer 9.1 7 18.2 6.06
Insulin signaling pathway 9 8.54 5.86 4.65
aThe negative natural logarithm of the enrichment P-value calculated for the specific pathway. Underlined shows higher enrichment in downregulated, upregulated,
or 14q32 miRNAs lists.
A computational analysis was performed to predict the network
and signaling pathways collectively targeted by the 64 downregu-
lated and 20 upregulated miRNAs. Downregulated miRNAs in MB
were predicted to target genes related to the ribosome, adherens
junction,oxidative phosphorylation,metabolism of xenobiotics by
cytochrome P450, and transforming growth factor-beta (TGF-β)
signaling pathways. Axon guidance,TGF-β,WNT, insulin signaling
pathways are known to play an important role in neurulation, CNS
developmental, and/or MB pathogenesis (3, 33, 34). Since miRNA
act as negative regulators of gene expression, a simpler interpreta-
tion of these findings is that MB has increased activation of these
pathways in comparison to normal cerebellum.
Most importantly, half (32/64) of downregulated miRNAs
reported in our study were found to belong to the cluster at 14q32
locus (also known as miR-154 cluster). This is in keeping with a
previous study in a mouse model of MB, reporting that activation
of SHH signaling leads to downregulation of the miR-154 clus-
ter (35). Moreover, previous publications with primary MB found
downregulation of some 14q32 miRNAs in MBs of the molecular
subgroups WNT, SHH, and C as compared to normal cerebellum
and MBs of subgroup D (13, 29). However, this is the first time that
so many 14q32 miRNAs are shown to be downregulated in MB,
thus suggesting a co-regulatory control of this cluster’s expression.
Deletions at locus 14q32 would be one possible explanation
to the decreased 14q32 miRNAs expression. The recent analy-
sis of somatic copy number aberrations in 1,087 MB samples
report significant losses of chromosome arm 14q in the SHH sub-
group of MBs, though not restricted to 14q32 (36). Alternative
explanations are discussed below. Our Ingenuity pathways analysis
pointed to nuclear orphan receptor NR0B2 (also known as Small
Heterodimer Partner, SHP) and (ESRRG) as possible controllers
of 14q32 miRNA cluster expression. There is indeed experimen-
tal evidence in mouse showing that NR0B2 is a repressor while
ESRRG is and activator of a miRNA cluster in chromosome 12,
which is ortholog to the 14q32 cluster in humans (37). Our analy-
sis of microarray mRNA expression data for 64 primary human
MB samples, accessible through GEO Series accession number
GSE28245 (38) in NCBI’s Gene Expression Omnibus (39) revealed
that NR0B2 is not expressed in MB. Interestingly, ESRRG expres-
sion was found to be relatively high in MBs of the molecular
subgroup D, intermediate in MBs of the WNT and C subgroups,
and very low or absent in MBs of the SHH subgroup (Figure A4A
in Appendix), thus reflecting 14q32 miRNAs abundance in each of
the MB subgroup. These findings were confirmed by the analysis
of gene expression data of an independent cohort of 90 pri-
mary MB samples (accession number GSE21166) deposited by
Northcott et al. (13) (data not shown). ESRRG suppress cell pro-
liferation in prostate cancer cells (40) and the estrogen receptor
beta agonist diarylpropionitrile (DPN ) exhibit a pro-apoptotic
and anti-proliferative effect on MB (41). Experiments are war-
ranted to investigate a possible causal connection between ESRRG
and 14q32 miRNA cluster expression in MB.
The miRNA cluster at 14q32 lies within a parentally imprinted
chromosomal area spanning genes Dlk1, Meg3, Rtl1, Meg8, and
Dio3 (42). Dlk1, Rtl1, and Dio3 are paternally-, whereas Meg3
and Meg8 are maternally expressed transcripts (43). Imprinting of
14q32 is regulated, to some extent, by two intergenic differentially
methylated regions known as IG-DMR and MEG3-DMR (44, 45).
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FIGURE 2 | Ingenuity pathway analysis networks (IPA). (A) Network 1; (B) Network 2; both were constructed with deregulated miRNAs in medulloblastoma.
Deletions of the regulatory regions and/or epigenetic modifica-
tions may in theory cause aberrant 14q32 silencing in cancer. The
recent 1,000 genome study of somatic copy number aberrations
shows no recurrent focal deletions at locus 14q32 in MB (36).
However, our analysis of public mRNA microarray expression data
GSE28245 (38) revealed that MEG3 is downregulated in MB in
comparison to normal cerebellum. MBs of the molecular group
C and WNT have the lowest expression, SHH has intermediate
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FIGURE 3 | Validation of miR-206, 129-5p, 323-3p, and 495
downregulation by reverse transcriptase-quantitative PCR.
Expression levels of miR-206, 129-5p, 323-3p, and 495 were
performed in MB, normal fetal/newborn cerebellum and four different
MB cell lines. Expression of miR-495 was not performed in D341 cell
line.©, DAOY; H, Meb-Med-8A; x, D283Med; ♦, D341. Comparisons
of MB versus normal cerebellum were done by the Mann–Whitney
test.
FIGURE 4 | Effect of miR-206, 129-5p, and 323-3p overexpression in
DAOY cells proliferation. DAOY cells were transiently transfected with
miRNAs mimic and replated after 20 h at a 1,500 cells/well density. Cell
proliferation was evaluated by the MTS assay at 4, 28, and 52 h after
re-plating, thus after 24, 48, and 72 h post-transfection. Results are
representative of three independent experiments. Mean±SE are shown;
**P <0.01 according to two-tailed t -test; NC, negative control miRNA
mimic (scrambled).
www.frontiersin.org September 2013 | Volume 3 | Article 254 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lucon et al. Downregulation of 14q32 microRNAs in medulloblastoma
levels while group D have MEG3 levels closer to normal cerebel-
lum (Figure A4B in Appendix). Thus MEG3 expression seems to
correlate with the expression of 14q32 miRNAs among the differ-
ent MB molecular groups, suggesting that the 14q32 miRNA locus
may be under epigenetic regulation in MB. However, a genome
wide analysis of promoter methylation on four primary MB sam-
ples showed no consistent methylation of 14q32 gene promoters
(46). Although higher number of samples should be analyzed, this
result corroborates findings in osteosarcoma, a tumor also present-
ing with downregulated 14q32 miRNAs expression and with no
consistent changes in the methylation patterns at 14q32. Instead,
silencing of 14q32 miRNA in osteosarcoma seems to be mediated
by histone modification(s) (47).
Preliminary functional studies were performed in DAOY cells
by ectopic expression of miR-129-5p, 206, and 323-3p mimics.
Mimics for miR-206 and 323-3p had no significant effect on
DAOY cells. miR-129-5p overexpression resulted in decreased cell
proliferation, which may suggest a tumor suppressor role in MB.
ACKNOWLEDGMENTS
We thank Dr. Carlos A Scrideli for helpful discussion and for the
cell line DAOY and Dr. Priscila P. Zenatti and Dr. Angelo B. A.
Laranjeira for technical assistance with FACS analysis. We also
acknowledge the Microarray Laboratory at Brazilian Biosciences
National Laboratory, CNPEM-ABTLuS, Campinas, Brazil for their
support with the use of Fluidics station and Scanner GeneChip
equipments. This work was supported by grant from Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2010/07020-
9). DRL have Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior PhD scholarship (2012/890912-1).
REFERENCES
1. Ellison D. Classifying the medul-
loblastoma: insights from mor-
phology and molecular genet-
ics. Neuropathol Appl Neurobiol
(2002) 28:257–82. doi:10.1046/j.
1365-2990.2002.00419.x
2. Gulino A, Di Marcotullio L, Fer-
retti E, De Smaele E, Screpanti I.
Hedgehog signaling pathway in
neural development and disease.
Psychoneuroendocrinology (2007)
32:S25–56. doi:10.1016/j.psyneuen.
2007.03.017
3. Kool M, Koster J, Bunt J, Has-
selt NE, Lakeman A, van SluisP,
et al. Integrated genomics identi-
fies five medulloblastoma subtypes
with distinct genetic profiles, path-
way signatures and clinicopatho-
logical features. PLoS ONE (2008)
3:e3088. doi:10.1371/journal.pone.
0003088
4. Northcott PA, Korshunov A, Witt
H, Hielscher T, Eberhart CG, Mack
S, et al. Medulloblastoma comprises
four distinct molecular variants. J
Clin Oncol (2010) 29:1408–14. doi:
10.1200/JCO.2009.27.4324
5. Gilbertson RJ, Ellison DW. The ori-
gins of meduloblastoma subtypes.
Annu Rev Pathol (2008) 3:341–65.
doi:10.1146/annurev.pathmechdis.
3.121806.151518
6. Schüller U, Heine VM, Mao J, Kho
AT, Dillon AK, Han YG, et al.
Acquisition of granule neuron pre-
cursor identity is a critical deter-
minant of progenitor cell compe-
tence to form SHH-induced medul-
loblastoma. Cancer Cell (2008)
14:123–34. doi:10.1016/j.ccr.2008.
07.005
7. Yang ZJ, Ellis T, Markant SL, Read
TA, Kessler JD, Bourboulas M, et
al. Medulloblastoma can be initiated
by deletion of Patched in lineage-
restricted progenitors or stem cells.
Cancer Cell (2008) 14(2):135–45.
doi:10.1016/j.ccr.2008.07.003
8. Gibson P, Tong Y, Robinson G,
Thomson MC, Currie DS, Eden C,
et al. Subtypes of medulloblastoma
have distinct developmental origins.
Nature (2010) 468:1095–9. doi:10.
1038/nature09587
9. Cohen SM. MiRNAs in CNS Devel-
opment and Neurodegeneration:
Insights from Drosophila Genet-
ics. Springer (2010). Available
from: http://www.springer.com/
978-3-642-04297-3
10. Sood P, Krek A, Zavolan M, Macino
G, Rajewsky N. Cell-type-specific
signatures of microRNAs on target
mRNA expression. Proc Natl Acad
Sci U S A (2006) 103(8):2746–51.
doi:10.1073/pnas.0511045103
11. Guo H, Ingolia NT, Weiss-
man JS, Bartel DP. Mammalian
microRNAs predominantly act
to decrease target mRNA levels.
Nature (2010) 466(7308):835–41.
doi:10.1038/nature09267
12. Ferretti E, De Smaele E, Po A,
Di Marcotullio L, Tosi E, Espínola
MSB, et al. MiRNA profiling in
human meduloblastoma. Int J Can-
cer (2009) 124:568–77. doi:10.1002/
ijc.23948
13. Northcott PA, Fernandez LA, Hagan
JP, Ellison DW, Grajkowska W,
Gillespie Y, et al. The miR-
17/92 polycistron is upregulated
in Sonic Hedgehog driven medul-
loblastomas and induced by N-
myc in Sonic Hedgehog-treated
cerebellar neural precursors. Can-
cer Res (2009) 69:3249–55. doi:10.
1158/0008-5472.CAN-08-4710
14. Cho YJ, Tsherniak A, Tamayo P,
Santagata S, Ligon A, Greulich H,
et al. Integrative genomic analy-
sis of medulloblastoma identifies
a molecular subgroup that dri-
ves poor clinical outcome. J Clin
Oncol (2011) 29(11):1424–30. doi:
10.1200/JCO.2010.28.5148
15. Fernandez LA, Northcott PA, Tay-
lor MD, Kenney AM. Normal and
oncogenic roles for microRNAs in
the developing brain. Cell Cycle
(2009) 8(24):4049–54. doi:10.4161/
cc.8.24.10243
16. Pfister SM, Korshunov A, Kool M,
Hasselblatt M, Eberhart C, Tay-
lor MD. Molecular diagnostics of
CNS embryonal tumors. Acta Neu-
ropathol (2010) 120:553–66. doi:10.
1007/s00401-010-0751-5
17. Livak KJ, Schmittgen TD. Analy-
sis of relative gene expression
data using real-time quantitative
PCR and the 2(-Delta Delta C(T))
method. Methods (2001) 25:402–8.
doi:10.1006/meth.2001.1262
18. Pietsch T, Scharmann T, Fonatsch
C, Schmidt D, Ockler R, Freihoff D,
et al. Characterization of five new
cell lines derived from human prim-
itive neuroectodermal tumors of the
central nervous system. Cancer Res
(1994) 54:3278–87.
19. Breitling R, Armengaud P, Amt-
mann A, Herzyk P. Rank products:
a simple, yet powerful, new method
to detect differentially regulated
genes in replicated microarray
experiments. FEBS Lett (2004)
573:83–92. doi:10.1016/j.febslet.
2004.07.055
20. Gautier L, Cope L, Bolstad
BM, Irizarry RA. Affy – analy-
sis of Affymetrix GeneChip
data at the probe level. Bioin-
formatics (2004) 20:307–15.
doi:10.1093/bioinformatics/btg405
21. Gentleman RC, Carey VJ, Bates
DM, Bolstad B, Dettling M,
Dudoit S, et al. Bioconductor:
open software development for
computational biology and bioin-
formatics. Genome Biol (2004)
5:R80.
22. Zhou J, Tian Y, Li J, Lu B,
Sun M, Zou Y, et al. miR-206
is down-regulated in breast can-
cer and inhibits cell prolifera-
tion through the up-regulation
of cyclinD2. Biochem Biophys Res
Commun (2013) 433(2):207–12.
doi:10.1016/j.bbrc.2013.02.084
23. Birks DK, Barton VN, Donson
AM, Handler MH, Vibhakar
R, Foreman NK. Survey of
MicroRNA expression in pedi-
atric brain tumors. Pediatr Blood
Cancer (2011) 56(2):211–6.
doi:10.1002/pbc.22723
24. Huang YW, Liu JC, Deatherage
DE, Luo J, Mutch DG, Goodfellow
PJ, et al. Epigenetic repression of
microRNA-129-2 leads to upregula-
tion of SOX4 oncogene in endome-
trial cancer. Cancer Res (2009)
69(23):9038–46. doi:10.1158/0008-
5472.CAN-09-1499
25. Shen R, Pan S, Qi S, Lin X,
Cheng S. Epigenetic repression of
microRNA-129-2 leads to upreg-
ulation of SOX4 in gastric can-
cer. Biochem Biophys Res Com-
mun (2010) 394(4):1047–52. doi:
10.1016/j.bbrc.2010.03.121
26. Neben K, Korshunov A, Benner A,
Wrobel G, Hahn M, Kokocinski F, et
al. Microarray-based screening for
molecular markers in medulloblas-
toma revealed STK15 as indepen-
dent predictor for survival. Cancer
Res (2004) 64(9):3103–11. doi:10.
1158/0008-5472.CAN-03-3968
27. de Bont JM, Kros JM, Passier
MM, Reddingius RE, Sillevis Smitt
PA, Luider TM, et al. Differential
expression and prognostic signif-
icance of SOX genes in pediatric
medulloblastoma and ependy-
moma identified by microarray
analysis. Neuro Oncol (2008)
10(5):648–60. doi:10.1215/
15228517-2008-032
Frontiers in Oncology | Pediatric Oncology September 2013 | Volume 3 | Article 254 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lucon et al. Downregulation of 14q32 microRNAs in medulloblastoma
28. Garzia L, Andolfo I, Cusanelli
E, Marino N, Petrosino G, De
Martino D, et al. MicroRNA-
199b-5p impairs cancer stem cells
through negative regulation of
HES1 in medulloblastoma. PLoS
ONE (2009) 4:4998. doi:10.1371/
journal.pone.0004998
29. Gokhale A, Kunder R, Goel A, Sarin
R, Moiyadi A, Shenoy A, et al.
Distinctive microRNA signature of
medulloblastomas associated with
the WNT signaling pathway. J Can-
cer Res Ther (2010) 6:521–9. doi:10.
4103/0973-1482.77072
30. de Antonellis P, Medaglia C,
Cusanelli E, Andolfo I, Liguori
L, De VitaG, et al. MiR-34a
targeting of notch ligand delta-
like 1 impairs CD15+/CD133+
tumor-propagating cells and
supports neural differenti-
ation in medulloblastoma.
PLoS ONE (2011) 6(9):e24584.
doi:10.1371/journal.pone.0024584
31. Grunder E, D’Ambrosio R,
Fiaschetti G, Abela L, Arcaro A,
Zuzak T, et al. MicroRNA-21
suppression impedes medul-
loblastoma cell migration. Eur
J Cancer (2011) 47:2479–90.
doi:10.1016/j.ejca.2011.06.041
32. Uziel T, Karginov FV, Xie S, Parker
JS, Wang YD, Gajjar A, et al. The
miR-17 92 cluster collaborates with
the Sonic Hedgehog pathway in
medulloblastoma. Proc Natl Acad
Sci USA (2009) 106:2812–7. doi:10.
1073/pnas.0809579106
33. Chédotal A, Kerjan G, Moreau-
Fauvarque C. The brain within the
tumor: new roles for axon guidance
molecules in cancers. Cell Death
Differ (2005) 12(8):1044–56. doi:
10.1038/sj.cdd.4401707
34. Aref D, Moffatt CJ, Agnihotri S,
Ramaswamy V, Dubuc AM, North-
cott PA, et al. Canonical TGF-b
pathway activity is a predictor of
SHH-driven medulloblastoma sur-
vival and delineates putative pre-
cursors in cerebellar development.
Brain Pathol (2013) 23:178–91. doi:
10.1111/j.1750-3639.2012.00631.x
35. Luo X, Liu J, Cheng SY. The role
of microRNAs during the gen-
esis of medulloblastoma induced
by the hedgehog pathway. Biomed
Res (2011) 25(1):42–8. doi:10.1016/
S1674-8301(11)60005-5
36. Northcott PA, Shih DJ, Peacock
J, Garzia L, Morrissy AS, Zich-
ner T, et al. Subgroup-specific
structural variation across 1,000
medulloblastoma genomes. Nature
(2012) 488(7409):49–56. doi:10.
1038/nature11327
37. Song G, Wang L. miR-433 and
miR-127 arise from independent
overlapping primary transcripts
encoded by the miR-433-127 locus.
PLoS ONE (2008) 3:e3574. doi:10.
1371/journal.pone.0003574
38. Remke M, Hielscher T, Korshunov
A, Northcott PA, Bender S, Kool
M, et al. FSTL5 is a marker of
poor prognosis in non-WNT/non-
SHH medulloblastoma. J Clin
Oncol (2011) 29(29):3852–61. doi:
10.1200/JCO.2011.36.2798
39. Edgar R, Domrachev M, Lash AE.
Gene expression omnibus: NCBI
gene expression and hybridization
array data repository. Nucleic Acids
Res (2002) 30:207–10. doi:10.1093/
nar/30.1.207
40. Yu S, Wang X, Ng CF, Chen S, Chan
FL. ERRgamma suppresses cell pro-
liferation and tumor growth of
androgen-sensitive and androgen-
insensitive prostate cancer cells and
its implication as a therapeutic
target for prostate cancer. Cancer
Res (2007) 67(10):4904–14. doi:10.
1158/0008-5472.CAN-06-3855
41. Mancuso M, Leonardi S, Giar-
dullo P, Pasquali E, Borra F, Ste-
fano ID, et al. The estrogen recep-
tor beta agonist diarylpropionitrile
(DPN) inhibits medulloblastoma
development via anti-proliferative
and pro-apototic pathways. Cancer
Lett (2011) 308(2):197–202. doi:10.
1016/j.canlet.2011.05.004
42. da Rocha ST, Edwards CA, Ito
M, Ogata T, Ferguson-Smith AC.
Genomic imprinting at the mam-
malian Dlk1-Dio3 domain. Trends
Genet (2008) 24:306–16. doi:10.
1016/j.tig.2008.03.011
43. Lin SP, Youngson N, Takada S, Seitz
H, Reik W, Paulsen M, et al. Asym-
metric regulation of imprinting on
the maternal and paternal chromo-
somes at the Dlk1-Gtl2 imprinted
cluster on mouse chromosome 12.
NatGenet (2003) 35:97–102. doi:10.
1038/ng1233
44. Takada S, Paulsen M, Tevendale M,
Tsai CE, Kelsey G, Cattanach BM, et
al. Epigenetic analysis of the Dlk1-
Gtl2 imprinted domain on mouse
chromosome 12: implications for
imprinting control from compari-
son with Igf2-H19. Hum Mol Genet
(2002) 11:77–86. doi:10.1093/hmg/
11.1.77
45. Kagami M, O’Sullivan MJ, Green
AJ, Watabe Y, Arisaka O, Masawa
N, et al. The IG-DMR and the
MEG3-DMR at human chromo-
some 14q32.2: hierarchical interac-
tion and distinct functional prop-
erties as imprinting control cen-
ters. PLoS Genet (2010) 6:e1000992.
doi:10.1371/journal.pgen.1000992
46. Diede SJ, Guenthoer J, Geng LN,
Mahoney SE, Marotta M, Olson
JM, et al. DNA methylation of
developmental genes in pediatric
medulloblastomas identified by
denaturation analysis of methy-
lation differences. Proc Natl Acad
Sci U S A (2010) 107(1):234–9.
doi:10.1073/pnas.0907606106
47. Thayanithy V, Park C, Sarver AL,
Kartha RV, Korpela DM, Graef
AJ, et al. Combinatorial treatment
of DNA and chromatin-modifying
drugs cause cell death in human
and canine osteosarcoma cell lines.
PLoS ONE (2012) 7(9):e43720. doi:
10.1371/journal.pone.0043720
48. Pierson J, Hostager B, Fan R, Vib-
hakar R. Regulation of cyclin depen-
dent kinase 6 by microRNA 124
in medulloblastoma. J Neurooncol
(2008) 90:1–7. doi:10.1007/s11060-
008-9624-3
49. Li KK, Pang JC, Ching AK, Wong
CK, Kong X, Wang Y, et al. miR-
124 is frequently down-regulated in
meduloblastoma and is a negative
regulator of SLC16A1. Hum Pathol
(2009) 40(9):1234–43. doi:10.1016/
j.humpath.2009.02.003
50. Ferretti E, De Smaele E, Miele E,
Laneve P, Pó A, Pelloni M, et al. Con-
certed miRNA control of Hedge-
hog signalling in cerebellar neuronal
progenitor and tumour cells. EMBO
J (2008) 27:2616–27. doi:10.1038/
emboj.2008.172
51. Venkataraman S, Alimova I, Fan
R, Harris P, Foreman N, Vib-
hakar R. MicroRNA 128a increases
intracellular ROS level by target-
ing Bmi-1 and inhibits medul-
loblastoma cancer cell growth by
promoting senescence. PLoS ONE
(2010) 5(6):e10748. doi:10.1371/
journal.pone.0010748
52. Genovesi LA, Carter KW, Got-
tardo NG, Giles KM, Dallas PB.
Integrated analysis of miRNA and
mRNA expression in childhood
medulloblastoma compared with
neural stem cells. PLoS ONE
(2011) 6(9):e23935. doi:10.1371/
journal.pone.0023935
53. Weeraratne SD, Amani V, Neiss A,
Teider N, Scott DK, Pomeroy SL,
et al. miR-34a confers chemosen-
sitivity through modulation of
MAGE-A and p53 in medul-
loblastoma. Neuro Oncol (2011)
13(2):165–75. doi:10.1093/neuonc/
noq179
54. Lv SQ, Kim YH, Giulio F, Shalaby T,
Nobusawa S, Yang H, et al. Genetic
alterations in MicroRNAs in medul-
loblastomas. Brain Pathol (2012)
22:230–9. doi:10.1111/j.1750-3639.
2011.00523.x
55. Wang XM, Zhang SF, Cheng
ZQ, Peng QZ, Hu JT, Gao LK,
et al. MicroRNA383 regulates
expression of PRDX3 in human
medulloblastomas. Zhonghua Bing
Li Xue Za Zhi (2012) 41(8):547–52.
doi:10.3760/cma.j.issn.0529-5807.
2012.08.009
56. Li KKW, Pang JCS, Lau KM, Zhou
L, Mao Y, Wang Y, et al. MiR-
383 is downregulated in medul-
loblastoma and targets peroxire-
doxin 3 (PRDX3). Brain Pathol
(2013) 23(4):413–25. doi:10.1111/
bpa.12014
57. Weeraratne SD, Amani V, Teider
N, Pierre-Francois J, Winter D,
Kye MJ, et al. Pleiotropic effects
of miR-183 96 182 converge to
regulate cell survival, proliferation
and migration in meduloblas-
toma. Acta Neuropathol (2012)
123:539–52. doi:10.1007/s00401-
012-0969-5
58. Venkataraman S, Birks DK, Balakr-
ishnan I, Alimova I, Harris PS, Patel
PR, et al. MicroRNA 218 acts as a
tumor suppressor by targeting mul-
tiple cancer phenotype-associated
genes in medulloblastoma. J Biol
Chem (2013) 228(3):1918–28. doi:
10.1074/jbc.M112.396762
59. Wei L, Yan-hua G, Teng-fei C,
Xiao-zhong P, Jian-gang Y, Zhen-
yu M, et al. Identification of dif-
ferentially expressed microRNAs by
microarray: a possible role for
microRNAs gene in medulloblas-
tomas. Chin Med J (2009) 122
(20):2405–11.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 01 July 2013; accepted: 10 Sep-
tember 2013; published online: 25 Sep-
tember 2013.
Citation: Lucon DR,Rocha CdS,Craveiro
RB, Dilloo D, Cardinalli IA, Cav-
alcanti DP, Aguiar SdS, Maurer-
Morelli C and Yunes JA (2013) Down-
regulation of 14q32 microRNAs in
primary human desmoplastic medul-
loblastoma. Front. Oncol. 3:254. doi:
10.3389/fonc.2013.00254
This article was submitted to Pediatric
Oncology, a section of the journal Fron-
tiers in Oncology.
Copyright © 2013 Lucon, Rocha,
Craveiro, Dilloo, Cardinalli, Cavalcanti,
Aguiar, Maurer-Morelli and Yunes. This
is an open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the origi-
nal author(s) or licensor are credited and
that the original publication in this jour-
nal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.
www.frontiersin.org September 2013 | Volume 3 | Article 254 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lucon et al. Downregulation of 14q32 microRNAs in medulloblastoma
APPENDIX
D
A
O
Y
M
E
B
M
E
D
8A
D
28
3
D
34
1
M
B
1
M
B
2
M
B
3
M
B
4
M
B
5
M
B
6
M
B
7
M
B
8
M
B
9
M
B
10 C
1
C
2
C
3
C
4
C
5
C
6
C
7
C
8
0.0
0.5
1.0
1.5
2.0
2.5
re
la
ti
v
e
O
T
X
2
e
x
p
re
s
s
io
n
D
A
O
Y
M
E
B
M
E
D
8A
D
28
3
D
34
1
M
B
1
M
B
2
M
B
3
M
B
4
M
B
5
M
B
6
M
B
7
M
B
8
M
B
9
M
B
10 C
1
C
2
C
3
C
4
C
5
C
6
C
7
C
8
0
10
20
30
40
50
60
70
re
la
ti
v
e
 P
T
C
H
1
 e
x
p
re
s
s
io
n
FIGURE A1 | Expression of OTX2 and PTCH1 in the different
primary medulloblastomas (MB), medulloblastoma cell lines
(named), and normal cerebellum (C). Total RNA (100 ng) was reverse
transcribed and gene expression was measured by qPCR, in triplicates,
using the SYBR method. Primers are available upon request to the
authors. Values were normalized to the HPRT endogenous control
gene. Relative expression values were calculated using the 2−∆∆Ct
method.
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FIGURE A2 |Transfection efficiency of miR-206, miR-129-5p, and
miR-323-3p in DAOY cells as evaluated by RT-qPCR. Cells transfected with
the scrambled mimic were included as negative control (NC). Values were
normalized to the RUN6B endogenous control RNA. Relative expression
values were calculated using the 2−∆∆Ct method. Bars represent mean±SD.
Comparisons were performed by the Mann–Whitney test.
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FIGURE A3 | Apoptosis analysis of DAOY cells at 24 and 48 h
post-transfection with miR-206, 129-5p, 323-3p, or negative
control mimics, as evaluated by Annexin V and propidium
iodide staining and FACS analysis. DAOY cells grown in
serum-free RPMI-1640 medium. The percentage of necrotic (Q1),
late apoptotic (Q2), viable (Q3), and early apoptotic (Q4) cells are
shown in the corresponding quadrants. NC, negative control
(scrambled mimic).
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FIGURE A4 | Gene expression graph for different microarray probes of
interest. Data from 64 primary human MB samples accessible through GEO
Series accession number GSE28245 (38) in NCBI’s Gene Expression
Omnibus. (A) probe sets for ESRRG. (B) Probe sets for MEG3. Samples were
grouped according to the molecular MB subgroups intoWNT, SHH, C, and D.
SHH desmoplastic was separated from SHH classic.
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